Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company, announced the appointment of Markus Loeffler, MD, MBA, as Chief Medical Officer (CMO). Dr. Loeffler brings over three decades of leadership in oncology drug development, having held senior roles at Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. He notably led the pivotal Phase III program for Lutathera®, a radiopharmaceutical approved for gastroenteropancreatic neuroendocrine tumors.
The appointment comes as Helix prepares to enter a more execution-focused phase, with multiple programs approaching key regulatory and clinical milestones. As CMO, Dr. Loeffler will lead the strategy and execution of Helix's clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab for first-line non-small cell lung cancer (NSCLC). He will also guide LEUMUNA™ toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
Thomas Mehrling, MD, PhD, CEO of Helix, commented, "I've had the privilege of working with Markus before, and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs. He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare LEUMUNA to enter the clinic."
Dr. Loeffler expressed enthusiasm about joining Helix at a pivotal stage, noting the company's pipeline combines strong scientific foundations with clear clinical development opportunities. He highlighted the potential of advancing L-DOS47 in combination with checkpoint inhibition and bringing LEUMUNA to its first clinical evaluation.
The significance of this appointment lies in Helix's strategic focus on advancing its pipeline. L-DOS47, an antibody-enzyme conjugate, is being developed as a combination therapy for NSCLC, a difficult-to-treat cancer. The planned Phase Ib/II trial with pembrolizumab, an immune checkpoint inhibitor, could provide a new treatment option for patients who have not responded to standard therapies. LEUMUNA, an oral immune checkpoint modulator, addresses a critical unmet need in post-transplant leukemia relapse, a challenging condition with limited therapeutic options.
Helix BioPharma is a clinical-stage oncology company focused on developing therapies for underserved patient populations. Its pipeline includes L-DOS47, LEUMUNA™, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. The company's shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCF), and listed on the Frankfurt Stock Exchange (FWB: HBP0). More information is available at Helix BioPharma.
This strategic appointment underscores Helix's commitment to advancing its pipeline and achieving key milestones. With Dr. Loeffler's proven expertise in guiding oncology drugs from early development to regulatory approval, the company is well-positioned to navigate the complexities of clinical trials and bring novel therapies to patients in need.
